Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) CEO Ram Aiyar sold 15,152 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $12.98, for a total transaction of $196,672.96. Following the transaction, the chief executive officer directly owned 74,848 shares of the company’s stock, valued at $971,527.04. This trade represents a 16.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Korro Bio Stock Performance
Shares of KRRO stock opened at $12.93 on Tuesday. Korro Bio, Inc. has a one year low of $5.20 and a one year high of $55.89. The company has a 50 day moving average price of $12.37 and a 200 day moving average price of $10.63. The firm has a market capitalization of $186.49 million, a price-to-earnings ratio of -1.11 and a beta of 3.07.
Korro Bio (NASDAQ:KRRO – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%. As a group, equities analysts forecast that Korro Bio, Inc. will post -5.38 EPS for the current fiscal year.
Institutional Investors Weigh In On Korro Bio
Korro Bio News Roundup
Here are the key news stories impacting Korro Bio this week:
- Positive Sentiment: Lifesci Capital reiterated a Strong-Buy view on Korro Bio and issued multiple forward EPS estimates that were generally better than the broader consensus, which can support investor confidence in the stock’s long-term outlook.
- Neutral Sentiment: The analyst firm also published updated estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029, and FY2030, but these forecasts still point to ongoing losses as Korro Bio remains a pre-profit biotech company.
- Negative Sentiment: CEO Ram Aiyar sold 15,152 shares at an average price of $12.98, cutting his ownership by 16.84%; the company said the sale was to cover tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment.
- Negative Sentiment: Director Jean Francois Formela sold 2,860 shares at $13.95 under a pre-arranged Rule 10b5-1 trading plan, reducing his position by 1.45%, adding to the recent insider-selling narrative around KRRO.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on KRRO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research report on Wednesday, April 8th. Clear Str raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. William Blair raised shares of Korro Bio from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Wall Street Zen raised shares of Korro Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald increased their price objective on shares of Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Friday, March 13th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.71.
View Our Latest Analysis on Korro Bio
About Korro Bio
Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.
The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.
Featured Articles
- Five stocks we like better than Korro Bio
- Why 1 Little-Known ETF Is Riding the AI Chip Shortage
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
